Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44

Experimental Lung Research

Volumn 40, Issue 10, 2014, Pages 475-484

  Quan, Yu Hua ^a   Kim, Byungji ^b   Park, Ji Ho ^b   Choi, Yeonho ^a,c   Choi, Young Ho ^a   Kim, Hyun Koo ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Korea University   (South Korea)

Author keywords

CD44; Hyaluronan cisplatin conjugate; Lung cancer

Indexed keywords

CISPLATIN; HERMES ANTIGEN; HYALURONIC ACID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NON SMALL CELL LUNG CANCER; ADENOCARCINOMA; APOPTOSIS; CELL LINE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; IMMUNOLOGY; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; HUMANS; HYALURONIC ACID; LUNG; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; UP-REGULATION;

EID: 84908597322     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2014.905656     Document Type: Article

References (48)

1. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68: 4311-4320.
2. Leung ELH, Fiscus RR, Tung JW, Tin VPC, Cheng LC, Sihoe ADL, Fink LM, Ma Y, Wong MP: Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PloS One. 2010;5: e14062.
3. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T: Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res. 2004;24: 2193-2200.
4. Thomas L, Byers HR, Vink J, Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 1992;118: 971-977.
5. Campo F, Panza L, Silvia Morel EJ, Ciani L, Ristori S: Synthesis of self-assembled boronated nanoparticles for BNCT. Arkivoc. 2007;210: 292-306.
6. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62: 4899-4902.
7. Marhaba R, Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35: 211-231.
8. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C: Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999;83: 866-869.
9. Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch C: Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol. 2008;89: 38-43.
10. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A, Jr., Kubalak S, Klewer SE, McDonald JA: Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest. 2000;106: 349-360.
11. Toole 1 BP: Hyaluronan in morphogenesis. Semin Cell Dev Biol. 2001;12: 79-87.
12. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4: 528-539.
13. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61: 1303-1313.
14. Day AJ, Prestwich GD: Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277: 4585-4588.
15. Han SE, Kang H, Shim GY, Kim SJ, Choi HG, Kim J, Hahn SK, Oh YK: Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target. 2009;17: 123-132.
16. Hua Q, Knudson CB, Knudson W: Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J Cell Sci. 1993;106(Pt 1): 365-375.
17. Illum L, Farraj NF, Fisher AN, Gill I, Miglietta M, Benedetti LM: Hyaluronic-acid ester microspheres as a nasal delivery system for insulin. J Control Release. 1994;29: 133-141.
18. Kuo JW, Swann DA, Prestwich GD: Chemical modification of hyaluronic acid by carbodiimides. Bioconjug Chem. 1991;2: 232-241.
19. Ohri R, Hahn SK, Hoffman AS, Stayton PS, Giachelli CM: Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium. J Biomed Mater Res A. 2004;70: 328-334.
20. Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2005;95: 930-935.
21. Jung T, Gross W, Zöller M, Jung T, Gross W, Zöller M: CD44V6 coordinates tumor matrix-triggeredmotility and apoptosis resistance. J Biol Chem. 2011;286: 15862-15874.
22. Ossipov DA: Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv. 2010;7: 681-703.
23. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11: 1173-1179.
24. Luo Y, Ziebell MR, Prestwich GD: A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2000;1: 208-218.
25. Cai S, Xie Y, Davies NM, Cohen MS, Forrest ML: Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci. 2010;99: 2664-2671.
26. Cohen MS, Cai S, Xie Y, Forrest ML: A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg. 2009;198: 781-786.
27. Jeong YI, Kim ST, Jin SG, Ryu HH, Jin YH, Jung TY, Kim IY, Jung S: Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2008;97: 1268-1276.
28. Xie Y, Aillon KL, Cai S, Christian JM, Davies NM, Berkland CJ, Forrest ML: Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm. 2010;392: 156-163.
29. Yunis AA, Arimura GK, Russin DJ: Human pancreatic carcinoma (mia paca-2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 2006;19: 128-135.
30. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R: Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998;17: 33-58.
31. Orian-Rousseau V: CD44, a therapeutic target formetastasising tumours. Eur J Cancer. 2010;46: 1271-1277.
32. Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4: 33-45.
33. Toole BP: Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res. 2009;15: 7462-7468.
34. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confersmetastatic potential to rat carcinoma cells. Cell. 1991;65: 13-24.
35. Rosenberg B: Platinum complexes for the treatment of cancer. Antibiot Chemother. 1978;3: 134-147.
36. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol. 1994;35: 1-9.
37. Cerroni B, Chiessi E, Margheritelli S, Oddo L, Paradossi G: Polymer shelled microparticles for a targeted doxorubicin delivery in cancer therapy. Biomacromolecules. 2011;12: 593-601.
38. Wang X, Guo Z: Targeting and delivery of platinum-based anticancer drugs. Chem Soc Rev. 2013;42: 202-224.
39. Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N: Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013;334: 338-345.
40. Nozoe T, Kohnoe S, Ezaki T, Kabashima A, Maehara Y: Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130: 334-338.
41. Pilarski LM, Masellis-Smith A, Belch AR, Yang B, Savani RC, Turley EA: RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes andmalignant B cells: a mediator in B cell malignancy? Leuk Lymphoma. 1994;14: 363-374.
42. Udabage L, Brownlee GR, Nilsson SK, Brown TJ: The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res. 2005;310: 205-217.
43. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000;60: 150-155.
44. Cheng C, Yaffe MB, Sharp PA: A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev. 2006;20: 1715-1720.
45. Sinha R, Kim GJ, Nie S, Shin DM: Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5: 1909-1917.
46. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100: 3983-3988.
47. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14: 6751-6760.
48. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res. 2008;14: 5646-5648.